Khondrion
Netherlands - NijmegenBiotechnology
Focus: Khondrion is a publicly traded Dutch biotech focused on mitochondrial disease treatments, operating a focused pipeline of rare disease candidates. The company occupies a niche but strategically important segment addressing unmet needs in mitochondrial dysfunction.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Khondrion
AI assessmentNot HiringNo open roles listed right now. Follow Khondrion to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
KH176
MELASClinical Trials (1)
NCT02544217A Dose-escalating Clinical Trial With KH176
Phase 1Help build intelligence for Khondrion
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.